AU2018201889B2 — Topical formulation for a jak inhibitor
Assigned to Incyte Holdings Corp · Expires 2020-03-05 · 6y expired
What this patent protects
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1 yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders. 1/7 …
USPTO Abstract
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1 yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders. 1/7 FIG.1 PARABEN PHASE PropyleneGyo USP AQUEOUS PHASE Methyl Paraben ix NF Purified Water USP Propyl Paraben NF 4Mix Edetate Disodium USP Polyethylene Glycol USP Mix ACTIVE PHASE API hoshateMixXANTHAN GUM PHASE OIL PHASE Propylene Glycol Light Mieral Oil F eUSP Glyceryl StearateX SE Polysorbate 20 NF Mx/Heat White Petrolatum i ___.:::Mix Cetyl Alcohol NF Emulsify Stearyl Alcohol NF Peoytao BP Dimethicone 360 t t NIF Mix /Cool Medium Chainj Triglycerides In Process Test Content Uniformity Topical formulation SFill in Tubes
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.